THU0661 CLINICAL RELEVANCE OF DETECTING ANTI-ADALIMUMAB ANTIBODIES WITH A DRUG-TOLERANT ASSAY
A. Background: Adalimumab (Ada) has proven effective in treating rheumatoid arthritis (RA) and spondyloarthropathies (SpA), although approximately 30% of responders will present secondary clinical failure. Immunocomplex formation between antibodies to Ada (ATA) and Ada can increase drug clearance. Most of the assays to measure ATA present drug interference. Currently, different assays are available to measure total ATA (free and complexed). Objectives: To compare the detection of ATA along Ada treatment between two assays: one drug-sensitive and another drug-tolerant assay. Study the association of ATA with the clinical status. Methods: This is a prospective observational study with 63 patients with rheumatic diseases under Ada treatment enrolled at Biological Therapy Unit of Hospital La Paz. Serum Ada levels were measured by ELISA and serum ATA levels by two assays: an in-house two-site (bridging) ELISA (bELISA) to detect uncomplexed ATA (free ATA) and a drug-tolerant assay developed by ImmundiagnostikÒ (Bensheim, Germany) (IDK) to measure simultaneously free and complexed ATA (total ATA). Samples were evaluated at 0, 0.2, 0.5, 1, 1.5 and 2 years after Ada initiation. Results: Out of the 63 studied patients, 12 (19%) had RA and the rest (51, 81%) had different spondyloarthropathies (24, 38%) ankylosing spondylitis, 9 (14%) psoriatic arthritis, 14 (22%) undifferentiated spondyloarthritis and 4 (6%) spondyloarthritis associated with inflammatory bowel disease).Thirty-one patients (49%) received concomitant methotrexate (26% RA patients and 74% SpA patients), 13 (21%) received another DMARDs associated to Ada and 19 (30%) were on monotherapy.Out of the 63 patients, in 27 (43%) no ATA were detected. Thirty six patients (57%), were IDK+ and 12 patients (19%) were bELISA+ (all of them IDK+).The presence of ATA by bELISA was associated with absence of serum Ada levels. However, most (78%) samples with complexed ATA had low circulating Ada levels (1.65 mg/ml in ATA+ vs 6.25 mg/ml in ATA-, p<0.0001). ATA appeared by IDK at earlier treatment stages than by bELISA, statistically different at all studied time points.In patients who dropped-out (30 patients, 48%) ATA detection was frequent and significant by both methods. Background: Collection of patient-reported outcomes (PROs) is an important aspect of modern treatment strategies. Electronic capture in waiting areas by touch screens is part of routine care in the Danish DANBIO registry 1 . It is not known whether this data collection can be replaced with electronic data entry from home. Objectives: To test the feasibility of online patient recruitment via touch screens and to investigate if electronic reporting of PROs from home (ELECTOR ITplatform) is comparable to reporting completed at the hospital among patients with rheumatoid arthritis (RA) or axial spondyloarthritis (AS). Methods: Patients with RA or AS were recruited via touch screens and randomized to one of two groups by a pre-computed list generated through DANBIO; the first group completing the PROs at home and then at the hospitalsite, and vice versa for the second group. All patients completed the Health Assessment Questionnaires (HAQ), the Visual Analogue Scales (VAS) for fatigue, pain and global health and the annual visit questions. Furthermore, AS patients completed the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and the BAS Function Index (BASFI). Pearson's Chi-square test, independent samples t-test and Mann-Whitney U test were calculated. Smallest detectable differences (SDDs), 95% confidence intervals (CIs) and intra-class correlation coefficients (ICCs) were calculated. Clinicaltrials.gov identifier: NCT02818478. Results: A total of 952 patients received invitation, 45% accepted, 127 patients were contacted by phone, and 56 (44%) gave consent to participate. 22 patients with RA and 20 patients with AS completed the trial. All differences between scores from home vs hospital were smaller than SDD, and all were non-significant (p<0.05), except for BASFI and BASDAI item 5. ICC ranged from 0.947-0.990 (p<0.00001). Annual visit questions showed 96% concordance between the two methods. 50% of the patients preferred from home data entry over hospital and 10% vice versa. Conclusions: Recruitment of patients for a randomized trial via touch screens was feasible. PROs collected from patients' own devices at home generated results comparable to results obtained from the existing touch-screen solution and were preferred by the patients. Background: SLE patients have a marked increased risk of venous (VTE) and arterial (AT) thrombosis, which is not fully explained by traditional risk factors or the presence of anti-phospholipid antibodies. Thrombosis is a major cause of damage accrual, morbidity, and mortality in SLE. A better understanding of the pathogenesis and development of new biomarkers to identify patients at risk are needed. Recent studies link leptin and tumor necrosis factor-like weak inducer of apoptosis (TWEAK) to subclinical atherosclerosis and galectin-3-binding protein (G3BP) to type I interferon activation and a pro-thrombotic environment. Objectives: To explore G3BP, interferon gamma-induced protein 10 (IP-10), soluble CD163 (sCD163), TWEAK, and leptin serum levels as predictors of venous and arterial thrombotic events, damage accrual, and all-cause mortality during long-term follow-up in a large cohort of Swedish SLE patients. Methods: Baseline clinical and paraclinical data including disease activity and damage scores (SLICC) were available from 167 SLE patients. VTE (deep vein thrombosis and/or pulmonary embolism) and AT (myocardial infarction and/or cerebrovascular incident) data were available with a median follow-up period of six years. Baseline serum G3BP, IP-10, sCD163, TWEAK, and leptin were quantified using ELISA. Univariate and multivariate analyses were conducted to asses associations between the serum biomarkers and the occurrence of VTE/AT, damage accrual, and death. Results: In the follow-up period 11 (7%) VTE and 12 (7%) AT events occurred. SLICC-scores increased in 79 (47%) patients, and 19 (11%) patients died. In the univariate Cox regression analysis G3BP levels were significantly associated with an increased risk of VTE (hazard ratio (HR) 1.10, 95% confidence interval (CI): 1.01-1.2, P=0.03). This persisted in the multivariate cox regression analyses when adjusting for age, gender, diabetes, antiphospholipid syndrome, and treatment with warfarin (HR 1.16, 95% CI: 1.04-1.31, P=0.01). None of the other serum biomarkers were associated with AT and VTE. No significant associations were observed between the biomarkers and changes in SLICC-scores or all-cause mortality. Conclusions: Our study identifies serum G3BP as a novel independent predictor of VTE in SLE. This may improve our understanding of VTE pathogenesis in SLE and aid future VTE risk stratification and prophylaxis. Background: Evaluation of disease activity is one of the most important assessments in SLE; several instruments have been developed based on clinical and laboratory information recorded by the physician. Patient-administered questionnaires provide useful information with significant time and cost saving. Indeed, patient-reported outcomes are gaining a central role as outcome measures.SLAQ is a patient-reported instrument for the assessment of disease activity in SLE. It consists of three scores: Patient Global Assessment question (PGA) about presence and severity of lupus activity over the past month, questions on 24 symptoms (SLAQscore) and a single Numerical Rating Scale (NRS) for disease activity (0 -10). Objectives: The aim of the study was to translate and to validate the SLAQ in Italian. Methods: The process of translation and cultural adaptation followed published guidelines (1). The final version of the questionnaire (SLAQit) was pretested in a group of 35 SLE patients to assess acceptability, comprehension and feasibility. The validity of the SLAQit was evaluated by its administering to consecutive SLE patients attending the outpatient's clinic or the inpatients wards. Internal consistency between the three components of the score was evaluated by Chronbach's alpha; the external validity was tested toward validated activity indices (SLEDAI and ECLAM) scored by a physician blinded to the SLAQ results. In a subgroup of 30 patients the questionnaire was administered twice at 2 weeks' interval to assess its reliability. Results: 137 patients were enrolled (92% female, mean age 43.1 years, mean disease duration 15.3 years). At enrollment, the median SLEDAI score was 2 (range 1-18) and 45% of patients had at least one organ damage (median 2, 1-8). The pilot test provided a good acceptability (99.9% of response rate) and feasibility (mean of 4.6±2.3 minutes to be completed, 1-10); moreover, the 100% of patients declared to comprehend the scope of the SLAQ and 67.5% declared no content comprehension problems. Internal consistency was very good between (NRS vs PGA vs SLAQscore (α=0.79). NRS and PGA showed a linear correlation with both ECLAM and SLEDAI scores (ρ=0.24, p=0.004 and ρ=0.45, p<0.001 respectively), while the correlation with the SLAQscore didn't reach the statistical significance. SLAQit showed a very high reliability by comparing the test-retest results (α>0.8 for NRS, PGA and SLAQscore). SLAQit scores resulted directly related to the patients age (p=0.002) and the SLICC score (p=0.003) while no correlation with disease duration was observed. Conclusions: SLAQit demonstrated to be acceptable, comprehensible and feasible in our routine clinical setting; it also showed good internal consistency; correlation with physician's driven instruments is weaker and the SLAQit was influenced by epidemiological and disease-related factors (i.e. damage), thus confirming that the disease perception from the patient's perspective can be different from physicians and influenced by several factors. The SLAQit can be considered a useful screening tool for the first assessment of the disease activity before the standard visit. Background: Disease activity in SpA is widely evaluated through BASDAI or ASDAS with no proven superiority between the two, in spite the more objective evaluation of ASDAS through the inflammatory markers. Objectives: The aim of this study was to evaluate the clinical quality and discriminating power between the above indices when subdividing patients with anti-TNF therapy according to their disease status indicated by BASDAI, ASDAS or PtGA. Methods: This prospective, observational study included 100 patients with definite SpA on biological therapy.Demographic, clinical and laboratory data was collected. Statistical analysis was performed with SPSS 20.0. Results: When used as an external criterion PtGA showed that 12% of patients had active disease with a PtGA of over 5 while 88% were classified as low disease activity.Mean ASDAS-CRP and ASDAS-ESR in the active group were 3.39 and 3.24.Mean BASDAI score in the high activity group according to PtGA was 5.66.We showed that both ASDAS scores had good discriminating capacities, with similar values when using the SMD (2.0034 [95% CI 1.29-2.71]).Based on PtGA,BASDAI outperformed ASDAS scores with a SMD of 3.3391 [95% CI 2.5334-4.1447]. ROC curves of the disease activity scores by using the PtGA ≥5
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